Last edition
News about "Julie Kim"
Japan Approves Takeda's ORZEYFUL (Oveporexton) for Narcolepsy Type 1
Japan approves ORZEYFUL (oveporexton) as the first and only medicine targeting the underlying cause of narcolepsy type 1, following positive phase 3 results.
Julie Kim | 24/08/2026 | By News Bureau | 105
US FDA Approves Takeda's ORZEYFUL for Narcolepsy Type 1
US Food and Drug Administration (FDA) approves Takeda's ORZEYFUL (oveporexton), the first orexin therapy to treat the underlying cause of Narcolepsy Type 1 in adults.
Julie Kim | 07/08/2026 | By News Bureau
Takeda Names Julie Kim as Future CEO Amid Strategic Growth Plans
The appointment follows a multi-year succession process, and Kim will also be proposed as a candidate for election to the Board at Takeda’s Annual General Shareholders Meeting in June 2026.
Julie Kim | 05/02/2025 | By Aishwarya | 693
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy